1-s2.0-S1751991820302333-main.pdf (2.6 MB)
Download file

Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?

Download (2.6 MB)
journal contribution
posted on 23.09.2020, 09:50 by Samuel Seidu, Linda Mellbin, Marcel Kaiser, Kamlesh Khunti
GLP-1 receptor agonists (GLP-1RAs) are recommended for patients with type 2 diabetes (T2D), particularly those at high cardiovascular risk. Oral semaglutide is the first oral GLP-1RA. In clinical trials, oral semaglutide 14 mg reduced mean HbA1c by approximately 1.1–1.5% and reduced body weight by up to 5 kg. These changes were significantly greater compared with empagliflozin, sitagliptin and liraglutide (p < 0.05 for estimated treatment differences at 52 weeks in patients on treatment without rescue medication use). The most common side effects were gastrointestinal, mainly mild-to-moderate and transient nausea. Oral semaglutide may change the paradigm of T2D treatment in primary care.

History

Citation

Primary Care Diabetes, 2020, https://doi.org/10.1016/j.pcd.2020.07.011

Author affiliation

Diabetes Research Centre, College of Life Sciences

Version

AM (Accepted Manuscript)

Published in

Primary Care Diabetes

Publisher

Elsevier BV

issn

1751-9918

eissn

1878-0210

Acceptance date

24/07/2020

Copyright date

2020

Available date

19/08/2021

Spatial coverage

England

Language

eng